{"id":2785,"date":"2025-02-03T15:39:17","date_gmt":"2025-02-03T12:39:17","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2785"},"modified":"2025-03-07T13:17:20","modified_gmt":"2025-03-07T10:17:20","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201\/","title":{"rendered":"Entrada Therapeutics recebe autoriza\u00e7\u00e3o do Reino Unido para iniciar ELEVATE-44-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">ELEVATE-44-201, um estudo cl\u00ednico de dose ascendente m\u00faltipla (MAD) de Fase 1\/2 do ENTR-601-44, foi autorizado pela Medicines and Healthcare Products Regulatory Agency (MHRA) e pelo Research Ethics Committee do Reino Unido para o ensaio cl\u00ednico de um produto medicinal investigacional. O estudo tem como objetivo tratar a distrofia muscular de Duchenne (DMD) em pacientes que t\u00eam uma muta\u00e7\u00e3o confirmada no gene DMD que \u00e9 pass\u00edvel de salto do exon 44.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">O que \u00e9 o estudo cl\u00ednico ELEVATE-44-201?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-44-201 \u00e9 um estudo global, de duas partes, randomizado, duplo-cego, controlado por placebo, de Fase 1\/2, que avalia a seguran\u00e7a, tolerabilidade e efic\u00e1cia do ENTR-601-44 em pacientes ambulatoriais com DMD que s\u00e3o pass\u00edveis de salto do exon 44.<\/p>","protected":false},"excerpt":{"rendered":"<p>ELEVATE-44-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[235,49,233,234,141,127,77,48],"class_list":["post-2785","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-44-201","tag-england","tag-entrada","tag-entrada-therapeutics","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-uk"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=2785"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/2785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/2788"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=2785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=2785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=2785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}